Phase 3, Multicenter Open-Label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for eight weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosis.

Date publication

mai 2020

Journal

Liver international : official journal of the International Association for the Study of the Liver

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DI MARTINO Vincent

Tous les auteurs :
Abergel A, Asselah T, Mallat A, Chanteranne B, Faure F, Larrey D, Gournay J, Loustaud-Ratti V, Di Martino V, Fouchard-Hubert I, Pol S, Bailly F, Samuel D, Tran A, Dodel M, Andant N, Lamblin G, Muti L, Reymond M, Teilhet C, Pereira B, Buchard B

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/32383275

Résumé

Genotype 1b is the most common HCV genotype worldwide, accounting for the largest proportion of infections in Europe, Russia, Latin America and Asia. Reducing treatment duration can improve adherence, reduce drug exposure and cost. Accordingly, we evaluated the efficacy of eight weeks fixed dose combination of grazoprevir-elbasvir in treatment-naïve patients, with non-severe fibrosis.

Référence

Liver Int.. 2020 May 8;: